Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for DENOSUMAB
- Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes
- Preserving Geriatric Muscle With an Osteoporosis Medication
- Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
- A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
- RANKL Antibody for Acute Charcot Neuro-osteoarthropathy
- ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer
- Osseointegrated Transdermal Femoral Amputation Prostheses
- Denosumab Treatment in CKD Patients at High Risk of Fracture
- Muscle Impact of Treating Osteoporosis
- Denosumab vs Alendronate After Vertebroplasty
- Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2
- Denosumab vs Zoledronate After Lumbar Fusion
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
- Denosumab vs Zoledronate After Vertebroplasty
- Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty
- Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
- Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
- A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
- Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery
- Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis
- A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
- A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva
- Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
- FITMI - First In Treating Male Infertility
- Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
- Desomumab vs Zoledronic Acid and Osteoporotic Compression Fracture
- Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
- PRevEnting FracturEs in Renal Disease - 1
- The Optimal Sequential Therapy After Long Term Denosumab Treatment
- The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy
- Denosumab and Screw Fixation for Osteoporotic Compression Fracture
- Denosumab and Osteoporotic Vertebral Compression Fracture
- Anabolic Therapy in Postmenopausal Osteoporosis
- A Study to Evaluate LY06006 and Prolia in Healthy Adults
- A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis
- A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
- A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
- Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors
- Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
- Romosozumab/Denosumab Study for Premenopausal IOP
- Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
- A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
- Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Women
- Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
- Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
- The DENOCHARCOT Trial
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects
- Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
- The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover
- Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
- A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.
- Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
- Alendronate Versus Denosumab in Kidney Transplant Patients
- Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users
- Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
- Osteoporosis in Primary Hyperparathyroidism
- RANKL Inhibition and Mammographic Breast Density
- Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
- Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
- Novel Combination Therapy for Osteoporosis in Men
- The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
- Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours
- Markers of Osteoporosis in Cystic Fibrosis
- Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
- Denosumab Sequential Therapy
- Denosumab for Smoldering Multiple Myeloma
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
- Breast Cancer Women on Aromatase Inhibitors Treatment
- Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
- Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
- Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas
- Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy
- Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
- Denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS)
- Open-label Extension Denosumab Study in Children and Young Adults With Osteogenesis Imperfecta
- RANKL Inhibition and Breast Tissue Biomarkers
- Comparative Antiresorptive Efficacy Discontinuation of Denosumab
- Reduced Dose-density of Denosumab for Unresectable GCTB
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
- Denosumab in Subjects With Giant Cell Rich Tumors of Bone
- Denosumab Treatment for Fibrous Dysplasia
- Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
- Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
- MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
- Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
- A Study to Evaluate the Denosumab in Healthy Adults
- Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
- Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
- Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
- Bisphosphonates for Prevention of Post-Denosumab Bone Loss
- ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
- Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
- Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
- Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women
- Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study
- Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
- Denosumab for the Treatment of Adult LCH
- Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
- Effect of Denosumab in Erosion Healing in RA
- Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
- Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
- Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
- Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
- Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)
- Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis
- Denosumab and Male Infertility: a RCT
- The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
- Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
- Denosumab Versus Bisphosphonates (Alendronate) in GIOP
- Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
- Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC
- Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients
- Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life
- A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
- Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
- RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints
- The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty
- Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
- Preventing Osteoporosis Using Denosumab
- 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
- Denosumab as an add-on Neoadjuvant Treatment (GeparX)
- Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children
- Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study
- Denosumab and MRI Breast Imaging
- Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa
- Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
- Osteoclast Inhibition and Bone Formation
- A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
- Denosumab Safety Assessment in Multiple Observational Databases
- Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
- Effects of Denosumab Therapy for Japanese
- Longjohn Amgen Study - Effect of Denosumab...
- Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
- Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
- TNFSF11 Inhibition and Fertility: a Prospective Study
- Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
- Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
- Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
- Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
- The Efficacy of Denosumab in Active Crohn's Disease
- Denosumab for Treating Periprosthetic Osteolysis.
- Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
- Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
- A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
- Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
- China HVT Safety, PK, PD
- Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.
- The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab
- Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
- Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
- Effect of Denosumab on Cellular Biomarkers in the Human Breast
- Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark
- Phase 2a Study on Intravenous Infusion of Autologous Osteoblastic Cells in Severe Osteoporosis
- Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
- Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
- Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
- Denosumab China Phase III Study
- Denosumab Administration After Spinal Cord Injury
- Effect of RANKL Inhibition on UV-induced Immunosuppression
- AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment
- A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
- Denosumab for Breast Cancer With Bone Mets
- Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
- Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women
- A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
- A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
- Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer
- Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab
- Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
- RA Denosumab on Bone Microstructure Study
- Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
- Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
- Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo
- Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
- Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty
- Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
- Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
- Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
- Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass
- Denosumab in Primary Hyperparathyroidism
- Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
- A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
- Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis
- Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
- A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
- Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
- Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
- Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty
- Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
- Effects of Denosumab on the Pharmacokinetics of Etanercept
- The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
- Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
- Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
- A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
- Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
- Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
- Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
- Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
- A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
- A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
- Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
- Study of Denosumab in Subjects With Giant Cell Tumor of Bone
- Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
- Denosumab Adherence Preference Satisfaction Study
- Study of Transitioning From Alendronate to Denosumab
- Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
- A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
- An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
- Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
- A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
- A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
- A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
- Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
- Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
- Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
- A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
- Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Clinical trials list
click for details